Sweden · Delayed Price · Currency is SEK Alleima AB Earnings Call Transcripts
Fiscal Year 2026
-
Order intake and revenues returned to organic growth, led by strong performance in umbilicals, medical, industrial heating, and aerospace. Kanthal delivered record margins, while cost-saving measures supported profitability amid ongoing market uncertainty and regional volatility.
-
Market uncertainty and Middle East instability led to lower order intake and revenues, but strong performance in medical, industrial heating, and Kanthal segments helped offset declines. Efficiency measures and a solid balance sheet support ongoing investments and resilience.
Fiscal Year 2025
-
2025 saw flat organic revenue amid geopolitical and market headwinds, with strong performance in medical, nuclear, and oil & gas offset by weakness in industrial and chem/petrochem. Efficiency measures and capacity expansions are underway, and a strong balance sheet supports continued strategy execution.
-
The company is executing a focused strategy to grow high-value segments like medical, nuclear, and industrial heating, supported by strong financials and targeted investments. Margin improvement, operational excellence, and sustainability are key priorities, with ongoing initiatives across all divisions to enhance growth and efficiency.
-
Order intake and revenues were flat year-over-year amid macroeconomic uncertainty, with strong backlogs in oil and gas, nuclear, and medical segments. Adjusted EBIT margin fell to 4.7% due to weak European markets, FX headwinds, and a maintenance shutdown. SEK 200m in annual savings targeted via restructuring, with a SEK 400m Q4 charge.
-
Organic revenues declined 4% year-over-year amid weak demand in Europe and North America, with adjusted EBIT margin at 9.5% and strong performance in oil & gas, nuclear, and medical segments. Q3 is expected to be seasonally weaker due to extended maintenance and continued FX headwinds.
-
Solid Q1 performance with 8% organic revenue growth and 10.5% adjusted EBIT margin, supported by strong backlog and diversified segment contributions. Guidance maintained for full-year CapEx and tax, with cautious outlook amid global uncertainty.
Fiscal Year 2024
-
Organic revenue grew 1% for the year and 3% in Q4, with strong performance in oil and gas, nuclear, and medical segments, while industrial and Europe lagged. Adjusted EBIT margin was 11.5% in Q4, and the board proposed a 15% higher dividend. CapEx guidance for 2025 is SEK 1.2 billion.
-
Organic order intake declined 8% year-over-year, mainly due to oil and gas and industrial heating, while revenues grew 3% organically and adjusted EBIT margin reached 7% despite currency headwinds. Strategic investments in nuclear and medical capacity, strong cash flow, and a robust financial position support continued growth amid mixed market conditions.
-
Flat organic revenue growth and strong cash flow marked Q2, with an adjusted EBIT margin of 11.1%. Backlog remains solid, and market sentiment is improving, though some segments face ongoing challenges from metal price volatility and customer delays.